ABSTRACT: Multiplexed biomarker protein detection holds unrealized promise for clinical cancer diagnostics due to lack of suitable measurement devices and lack of rigorously validated protein panels. Here we report an ultrasensitive electrochemical microfluidic array optimized to measure a four-protein panel of biomarker proteins, and we validate the protein panel for accurate oral cancer diagnostics. Unprecedented ultralow detection into the 5−50 fg·mL −1 range was achieved for simultaneous measurement of proteins interleukin 6 (IL-6), IL-8, vascular endothelial growth factor (VEGF), and VEGF-C in diluted serum. The immunoarray achieves high sensitivity in 50 min assays by using off-line protein capture by magnetic beads carrying 400 000 enzyme labels and ∼100 000 antibodies. After capture of the proteins and washing to inhibit nonspecific binding, the beads are magnetically separated and injected into the array for selective capture by antibodies on eight nanostructured sensors. Good correlations with enzyme-linked immunosorbent assays (ELISA) for protein determinations in conditioned cancer cell media confirmed the accuracy of this approach. Normalized means of the four protein levels in 78 oral cancer patient serum samples and 49 controls gave clinical sensitivity of 89% and specificity of 98% for oral cancer detection, demonstrating high diagnostic utility. The low-cost, easily fabricated immunoarray provides a rapid serum test for diagnosis and personalized therapy of oral cancer. The device is readily adaptable to clinical diagnostics of other cancers.
M easurement of panels of biomarker proteins holds great promise for early cancer detection, for guidance for personalized therapy, and for drug development. 1, 2 Such tests can offer a "snapshot" of a patient's disease status 3, 4 and provide much more reliable diagnostics than single biomarkers. 5 The approach is not yet widely realized due to the lack of suitable measurement devices and the lack of rigorously validated protein panels. 3 For broad clinical applicability, new devices are needed that offer low cost, high sensitivity, and accuracy and require minimal technical expertise. Point-of-care analyses are preferred over off-site determinations, posing an even more formidable bioanalytical challenge. Herein, we demonstrate a simple, ultrasensitive microfluidic array optimized to detect four proteins simultaneously at attomolar levels, and we use it to validate a protein panel for oral cancer detection.
Oral cancer is generally classified as head and neck squamous cell carcinoma (HNSCC) and is the sixth most common cancer in the developed world. 6 HNSCC is associated with poor prognosis due to its asymptomatic nature, leading to late diagnoses that compromise therapeutic outcome. HNSCC is diagnosed mainly by visual detection of suspected cancerous lesions in the oral cavity that are often benign. 7 More sophisticated and accurate approaches to diagnose HNSCC are urgently needed, especially since early detection can improve survival. 8 Recent research has addressed detection and monitoring of HNSCC. For example, an electrochemical array designed to measure oral cancer biomarker proteins gave detection limits (DL) of 7.4 pg·mL −1 for interleukin 8 (IL-8) and 4 fM for IL-8 mRNA, 9 with ∼90% clinical sensitivity and specificity for cancer detection. Four salivary mRNA biomarkers were detected with a microarray with clinical sensitivity and specificity of 91%. 10 A biochip was developed to determine epidermal growth factor receptor (EGFR), nuclear area, and nuclear-to-cytoplasmic (N/C) ratio in exfoliated oral lesions, with 97% sensitivity and 93% specificity for detection of malignant and premalignant lesions, 11 but it requires cell-cytology samples collected by trained professionals. Single protein enzyme-linked immunosorbent assays (ELISA) were used to measure a five-protein panel in saliva with sensitivity of 90%, and specificity of 83% for oral cancer. 12 These reports document progress in new approaches for oral cancer detection, but biomarker-based methodologies are not generally available in the clinic.
Herein we demonstrate the clinical utility of a low-cost array for simultaneous determinations of four HNSCC biomarker proteins in serum. The diagnostic protein panel includes interleukin 6 (IL-6), IL-8, and vascular endothelial growth factor (VEGF), which are elevated in serum of HNSCC patients, 13, 14 and VEGF-C, which is associated with HNSCC metastasis. 17, 18 Serum IL-6 in patients with HNSCC ranges from ≥20 pg·mL in healthy individuals. 16 Similarly, serum IL-8 ≥ 20 pg·mL
suggests the presence of HNSCC, while normal levels 14 are ≤13 pg·mL −1 . Normal serum VEGF is ≤200 pg·mL −1 compared to ≥500 pg·mL −1 in patients with HNSCC. 15 Cancer patient serum VEGF-C 19, 20 is in the nanograms per milliliter range. On the basis of these expected levels in serum, analytical targets include sensitivity into the low picograms per milliliter range for IL-6, IL-8, and VEGF but lower sensitivity for VEGF-C.
ELISA is the gold standard for clinical protein measurements, but it typically determines one protein per sample and is limited by sample volume and analysis time. Multiplexed methods for proteins have been based on polynucleotide "barcodes" 21−23 and giant magnetoresistance arrays. 24 Optical detection on antibody microarrays holds promise but requires amplification. 25 Commercial multiplexed bead platforms 3, 26 have detection limits from 1 to 100 pg·mL −1 , but they require considerable technical expertise and have relatively high costs.
Electrochemical detection facilitates simple, inexpensive diagnostic arrays. 3, 27 We developed nanostructured amperometric immunosensors using multilabel strategies for detection of single protein prostate-specific antigen (PSA) 28, 29 and IL-6 in serum. 30 We used four-electrode carbon nanotube arrays for simultaneous measurement of four proteins in serum of prostate cancer patients. 31 In collaboration with Munge, we developed a single-protein sensor with unprecedented DL of 1.0 fg·mL −1 for IL-8 by combining gold nanoparticle (AuNP) surfaces with magnetic beads massively labeled with horseradish peroxidase (HRP) enzyme labels. 32 Nanostructured sensors facilitate attaching large populations of antibodies 33 that complement the large number of labels on detection particles to provide high sensitivity and ultralow DLs.
For the present work, we use an array of nanostructured sensors and massively labeled paramagnetic detection beads in a simple microfluidic device for ultrasensitive, multiplexed detection of proteins. This device consists of an AuNP immunoarray in a microchannel interfaced with a syringe pump and commercial sample injector. 34 Different antibodies are attached to the eight sensor elements, and paramagnetic beads (MB) loaded with 400 000 HRPs and thousands of secondary antibodies are used to capture analyte proteins from the sample off-line. Bead washing and magnetic separation is used during the off-line capture to lower nonspecific binding, and the actual sample never comes in contact with the measuring sensor array. MBs that have captured proteins are injected and incubated with the eight sensors such that sensor antibodies bind their specific protein partners attached to MBs. In a proof of concept study, we used this approach employing 200 000 HRPs per MB to achieve DLs of 0.23 pg·mL −1 for PSA and 0.30 pg·mL −1 for IL-6.
34
The present paper reports optimization of the microfluidic array to enable ultrasensitive simultaneous measurement of IL-6, IL-8, VEGF, and VEGF-C in serum. Excellent sensitivities and DLs into the low femtogram per milliliter range were obtained by increasing the number of labels to 400 000/bead. Measurements on cancer cell growth media gave excellent correlations with ELISA to confirm accuracy. The arrays were then used to validate a four-biomarker protein panel for oral cancer by analyzing 78 serum samples from oral cancer patients and 49 cancer-free controls. Statistical analysis indicated clinical specificity of 98% and sensitivity of 89% for oral cancer detection based on normalized means of the four-protein assays.
■ EXPERIMENTAL SECTION
Full details are given in Supporting Information.
Chemicals and Materials. Antibodies for IL-6, IL-8, VEGF, and VEGF-C and protein standards were from R&D Systems. Bovine serum albumin (BSA) and calf serum were from Sigma− Aldrich. Biotinylated horseradish peroxidase (HRP) was from Invitrogen. Screen-printed carbon sensor chips were from Kanichi Research. All other chemicals were from Sigma−Aldrich. The poly(dimethylsiloxane) (PDMS) kit was from Dow Corning. Streptavidin-coated magnetic beads (1 μm diameter Dynabeads) were from Invitrogen. Immortalized HaCaT cells, 35 oral keratinocyte cells, 36 and oral cancer cell lines 35, 37 were established as described previously.
Human Microfluidic Immunoarray. The microfluidic device was fabricated as described previously. 34 Glutathione-decorated AuNPs (5 nm) were coated onto sensor elements onto a thin layer of poly(diallydimethylammonium chloride) (PDDA). 29 An eight-electrode CHI 1030 electrochemical workstation was used for amperometric detection at the optimized potential of −0.3 V versus Ag/AgCl, 22 ± 2°C and 100 μL·min 1% BSA in PBS, followed by washing with 0.05% Tween-20 in PBS.
Synthesis of Ab 2 -MB-HRP Bioconjugates. Biotinylated HRPs and Ab 2 were attached to streptavidin-coated magnetic beads (MB) at a 500:1 HRP/Ab 2 molar ratio. After reaction, beads were magnetically separated in a well of an Invitrogen DynaMag-spin magnet. Then, 100 μL of 0.1% BSA was added and the mixture was vortexed to form a dispersion. Ab 2 -MB-HRP were stable for ∼14 days at 4°C.
Immunoassay Development. Ab 2 -MB-HRP bioconjugates were used to capture analyte proteins in mixtures outside the microfluidic channel, as summarized in Figure 1 . Briefly, 5 μL of Ab 2 -MB-HRP for each protein were combined together to give a 20 μL mixture, which was dispersed in 60 μL of 0.1% BSA in PBS. Twenty microliters of standard solution or sample was added to the dispersion, which was stirred on a slow tilt rotator for 25 min. Then MBs with captured proteins were magnetically separated and washed 2× with 0.1% BSA in PBS, and 110 μL of 0.1% BSA in PBS was added to the separated particles. The mixture was vortexed, injected into the 100 μL sample loop, and then injected into the microfluidic channel. When MBs reached the measurement chamber, as evidenced by their red-brown MB color, flow was stopped for 20 min, and then the channel was washed with 0.05% Tween-20 and PBS. Amperometry was done at −0.3 V versus Ag/AgCl while 50 μL of 100 μM H 2 O 2 in 1 mM hydroquinone was injected. Conditioned cell media samples were diluted in calf serum to mimic a complex biological matrix. Human patient serum samples were diluted 6000-fold in PBS to bring protein concentrations into the sensitivity range of the device.
Statistical Analysis. Receiver operating characteristic (ROC) analyses of patient sample data were done with MedCalc 
■ RESULTS
Immunoarray Performance in Serum. Preliminary binding studies showed acceptably low cross-reactivity for all antibodies. The protein analytes were selectively captured offline from samples on the Ab 2 -MB-HRP before analysis, with one type of bead designed to capture each of the four biomarkers. Ab 2 -MB-HRP beads were stable for at least 2 weeks at 4°C in PBS. From enzyme activity assays 38 ( Figure S2 , Supporting Information), we estimated 3.9 × 10 5 active HRPs/MB. A total protein assay was used to estimate 1.2 × 10 5 Ab 2 /MB ( Figure S3 , Supporting Information).
Sensor elements ( Figure S1 , Supporting Information) were coated with a dense layer of 5 nm diameter glutathione-decorated gold nanoparticles (AuNPs). Our previous atomic force microscopy (AFM) and microbalance studies 29 showed the approach used provides a nearly complete monolayer of AuNPs on the PDDA underlayer. Carboxylates from glutathione were covalently attached to amine groups on antibodies. The sensor chip was then assembled into the device and connected to the pump. After 1% bovine serum albumin (BSA) was flowed into the microfluidic channel, flow was stopped for 10 min, followed by washing with Tween-20 and PBS.
Ab 2 -MB-HRP were dispersed in 0.1% BSA in PBS, and protein samples (20 μL) were added and stirred. MBs were magnetically separated, washed with 0.1% BSA to minimize nonspecific binding (NSB), and then injected into the microfluidic channel. MBs with captured proteins are selectively bound to respective sensor elements during a 20 min quiescent period. Hydroquinone mediator and H 2 O 2 were subsequently injected to develop signals. H 2 O 2 activates HRP to a ferryloxy form that is reduced by the mediator, which shuttles electrons to the HRP labels (Scheme S1, Supporting Information). Assay time from incubation of sample with Ab 2 -MB-HRP to measurement was ∼50 min.
A separate, disposable eight-sensor chip was used for each run. Multiplexed detection of the four biomarkers in duplicate on a single array chip is illustrated in Figure 2A . The array provides reproducible peaks with high signal/noise for each protein (Figure 2A,B) . Peak current is proportional to protein concentration in the femtogram per milliliter range for all proteins (Figure 2C−F; Figure S4 , Supporting Information). Peaks for the zero protein controls are caused by a combination of direct amperometric peroxide reduction and residual NSB from Ab 2 -MB-HRP.
Limits of detection (DL) for each biomarker in calf serum (3 times the SD above the zero protein control) were 10 fg·mL
for IL-6 and IL-8 and a bit higher for VEGF and VEGF-C (Table S1 , Supporting Information). Excellent array-to-array reproducibility is illustrated in Figure 2A and by the small error bars at each concentration ( Figure 2C−F) . Detection of Hypoxia-Dependent Proteins in Normal Cells. Hypoxia promotes malignant progression 39 and upregulates growth factor VEGF 40 and cytokines IL-6 and IL-8. 41, 42 Immortalized normal oral keratinocytes (NOKsi) were cultured under normoxic and hypoxic conditions for 48 h, and biomarkers in the conditioned media were measured by the immunoarray and individual ELISAs. Figure 3E illustrates excellent correlation with ELISA. Under normoxia, proteins levels were too low to be detected by ELISA but were readily measurable by the array. Correlations were confirmed by linear correlation plots ( Figure S7E , Supporting Information).
Analysis of Serum from Oral Cancer Patients. The high sensitivity of the array permitted high dilution of patient serum to help decrease NSB. Calibrations were done by use of standards in 6000-fold diluted calf serum to mimic similarly diluted human serum. Linear dynamic ranges and sensitivities in diluted serum were about the same as in undiluted calf serum, but significant improvements in DL were found (Table S1 , Supporting Information): 5 fg·mL −1 for VEGF and IL-6 (∼250 aM), 10 fg·mL −1 for IL-8, and 50 fg·mL −1 for VEGF-C (Table S1 and Figure S5 , Supporting Information).
Sera from 78 oral cancer patients and 49 cancer-free controls were analyzed with the immunoarray. Clinical and histopathological evaluation of metastasis status was according to criteria from the World Health Organization (WHO). 43 Clinical staging provides information related to tumor size and metastasis (Table S2 , Supporting Information).
Receiver Operating Characteristic Analysis of Human Serum Data. Patient biomarker data were analyzed by receiver operating characteristic (ROC) plots. 44 In ROC, true positive rate (sensitivity) is plotted against the false positive rate (1 − specificity) for a series of decision thresholds. The closer the ROC curve comes to the upper left corner, the higher the overall accuracy. The area under the ROC curve (AUC) measures diagnostic value and allows computation of other parameters that monitor clinical utility (Table S3 , Supporting Information). ROC curves for the four proteins in human serum samples are shown in Figure 4A . We divided protein concentration for each sample by the respective standard deviation of levels of that protein in all samples, and then we averaged these values for each sample to give a single normalized parameter characteristic of levels of all measured proteins. Sensitivity and specificity of the panel results improved significantly when the normalized fourbiomarker values were used (Table S3 , Supporting Information). Principal component analysis ( Figure S8 , Supporting Information) showed that all four biomarkers contribute about equally to the variance, and their contributions to selectivity and sensitivity of cancer prediction are nearly equivalent.
For the normalized, mean function of the four-protein levels ( Figure 4B ), the ROC plot had an AUC of 0.96, larger for any individual biomarker protein. The normalized mean gave 89% sensitivity and 98% specificity, better than that of single proteins. The positive predictive value (PPV) was 98.6% and the negative predictive value (NPV) was 84%, also indicating excellent accuracy for oral cancer diagnosis (Table S3 , Supporting Information). t-tests showed a significant difference between the means of cancer and control samples for the four-biomarker normalized data (p < 0.001).
We also evaluated the possibility of differentiating early-and advanced-stage HNSCC from cancer-free controls. Figure 5 compares results for early (Tis, T1, T2) and late (T3, T4; see Table S2 , Supporting Information) stage tumors to cancer-free controls (con) and also to each other. The normalized fourbiomarker data show clear delineations for the three classes. The mean normalized value for samples with no indication of cancer was 0.20 ± 0.11, which differed significantly from 0.82 ± 0.30 (p < 0.001) for samples with early-stage tumors and 1.05 ± 0.53 (p < 0.001) for late-stage (T3, T4) tumors. Means for early-and late-stage tumors were significantly different (p < 0.05).
ROC analysis of control versus early-stage oral cancer gave an AUC of 0.98 and 89% sensitivity and 96% specificity ( Figure 5B ). These results indicate an excellent ability of the biomarker panel to detect early-stage tumors. When advanced-stage tumors and controls were compared, AUC of 1.00 and 100% sensitivity and specificity were found, clearly showing the ability to differentiate cancer-free individuals from those with late-stage HNSCC. ROC suggested that the panel has difficulty distinguishing between early-and late-stage cancer (Table S2 , Supporting Information). 
■ DISCUSSION
Results document the simultaneous detection of four cancer biomarker proteins with ultralow DLs by use of the immunoarray in serum and diluted serum. Considering single-protein assays, PCR barcode achieved DL 1 fg·mL −1 (30 aM) for prostatespecific antigen (PSA) in serum, and an amplified magnetoresistive sensor detected 50 aM carcinoembryonic antigen (CEA) in buffer. 22 Luminescent microbead arrays detected PSA at 14 fg·L −1 (420 aM). 45 We used superparamagnetic bead labels with surface plasmon resonance to detect 10 fg·mL −1 (300 aM) PSA in serum, 46 and we used enzyme-labeled magnetic beads with an amperometric sensor to detect 1 fg·mL −1 (100 aM) IL-8. 32 DLs in the low femtomolar range for protein mixtures were reported for a magnetoresistive array 24 and a rolling circle microarray for IL-6 and IL-8 in buffer. 47 In contrast, our microfluidic array detected four proteins simultaneously in dilute serum with subfemtomolar DLs (∼250 aM for IL-6): 5 fg·mL −1 for IL-6, 10 fg·mL −1 for VEGF and IL-8, and 50 fg·mL
for VEGF-C. DLs for this device are 100−1000-fold better than commercial multiprotein bead assays. 3, 26 Off-line capture of analyte proteins by antibody-linked magnetic beads labeled with 400 000 HRPs facilitates the ultrasensitive response of the microfluidic array. Equipping the MBs with multiple antibodies (∼100 000 Ab 2 /MB) drives binding equilibria toward very efficient protein capture due to the large local concentration of antibodies. These features combine to provide high sensitivity and ultralow DLs for IL-6, IL-8, VEGF, and VEGF-C in mixtures. Assay requires only 50 min and 5 μL of serum, significantly less on both counts than classic ELISA and commercial detection platforms.
Accuracy of determinations in complex mixtures was demonstrated by correlations of array results with ELISA on conditioned media from a range of normal and oral cancer cells (Figure 3 ; Figure S7 , Supporting Information). Selectivity was confirmed by accurate detection of individual biomarkers in these samples that contain many other potentially interfering proteins.
Stellar analytical performance of a device fabricated by lowcost nonlithographic machining makes this a viable prototype for future cancer diagnostics in the clinic. The disposable eightelectrode chips cost about ∼$9 each, syringe pump and injector cost about $6000, and electrochemical analyzers at $6000− $20 000 are used. Thus, ease of fabrication and utilization of commercial components makes this approach accessible to virtually any biomedical laboratory at a small cost.
Excellent reliability of the biomarker panel for detecting oral cancer was demonstrated by measuring four biomarker proteins in serum from patients presenting different stages of HNSCC. The AUC from ROC analysis of 0.96 for normalized mean biomarker values was larger than for any individual protein (Table S3 and Figure S4 , Supporting Information). The panel achieved clinical sensitivity of 89% and specificity of 98%. While late-stage tumors are detected with nearly 100% sensitivity and specificity, early-stage tumors are also detected with excellent sensitivity (89%) and specificity (96%) ( Figure 5 ).
To summarize, a novel, low-cost immunoarray was optimized for multiplexed detection of a panel of four biomarker proteins for oral cancer. This is the first microfluidic immunoarray capable of detecting multiple proteins at 5−50 fg·mL −1 (attomolar) levels. The device was used here to validate the panel of four proteins as having significant value in oral cancer diagnostics. This relatively simple diagnostic device provides a reliable platform for developing clinically useful protein detection devices that could in future be translated to point-of-care.
